• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Supply fears lead EU vaccine industry to seek home comforts

September 17, 2021 by David Barret Leave a Comment

September 17, 2021

By Ludwig Burger and Patricia Weiss

FRANKFURT (Reuters) – European companies playing key supporting roles in COVID-19 vaccine manufacturing are working to move production and supply chains closer to their customers to guard against trade restrictions that have interrupted supplies during the pandemic.

Germany’s Merck KGaA, whose Life Science unit is one of the world’s largest makers of bioreactor gear and supplies, told Reuters it is pushing to spread its production network geographically so that fewer shipments have to cross customs borders.

U.S. regulations in particular, which give priority to companies fulfilling U.S. government contracts, have posed a challenge for Merck as its seeks to meet soaring demand for supplies such as sterile fermentation bags and filters.

But the United States is not the only country engaging in what some call vaccine nationalism. India barred vaccine exports in mid-April to focus on its domestic immunisation drive as infections exploded across the country, upsetting the inoculation plans of many African and South Asian countries.

In the wake of production shortfalls at AstraZeneca earlier this year, the European Union imposed an export-monitoring scheme and accused Britain of withholding COVID-19 vaccine volumes that it said should be shared with the EU.

“Every forward-looking decision we have made integrated the geographical dimension into it,” Chief Executive Belen Garijo told Reuters. “In the context of the trade constraints that we have seen, we have enhanced our global diversification any time we had the chance,” she added.

At Rentschler Biopharma SE, a German contract manufacturer for major pharma companies that is helping to produce CureVac’s COVID-19 vaccine candidate, the pandemic triggered a review of its procurement routes.

“The coronavirus crisis gave us an important push to bring our supply chains closer to home. We decided to source most of our equipment in Europe so that we are no longer as dependent on the United States,” said Chief Executive Frank Mathias, naming sterile bags for bioreactors as an example. He would not name suppliers.

Mathias said supply chains collapsed earlier this year when the United States commandeered certain volumes for domestic vaccine producers.

The U.S. Defense Production Act with its system of rated orders that prioritise U.S. crisis response, also hobbled Merck’s ability to serve vaccine makers elsewhere in the world.

In response, Merck in March laid out plans to invest 25 million euros in France to make disposable plastic materials for bioreactors, an essential input for COVID-19 vaccine manufacturing.

The new site, Merck’s first such facility in Europe, will likely come on stream at the end of 2021, adding to similar production lines in runs in the U.S. and China.

That followed it investing $47 million in its U.S. facilities in Massachusetts and New Hampshire in December, at the time touted as strengthening its global output to meet unprecedented demand.

“The pandemic has been a wakeup call,” said Merck’s Garijo. “You want to have a global footprint in order to be able to deal with potential trade constraints.”

Family-controlled Merck also makes prescription drugs and chemicals for semiconductor production, but its Life Science unit, mostly made up of businesses formerly known as Millipore and Sigma Aldrich, has become its main earnings driver.

Its competitors include Thermo Fisher, Danaher and Sartorius.

In another move to avoid long transport routes and any fallout from international wrangling, German family-owned vaccine maker IDT Biologika earlier this year laid out plans to invest more than 100 million euros to produce AstraZeneca’s COVID-19 vaccine in collaboration with the Anglo-Swedish drugmaker.

The production line, currently set to come on stream in 2023, would be designed to churn out Astra’s shots or other vaccines of the same viral vector class, to the tune of at least 360 million doses a year.

IDT would make the active ingredient and mix, bottle and pack the final product, combining in one place a suite of production steps that are currently widely scattered.

IDT said the project was on track but declined to comment further. The company has said Germany’s federal health ministry had assisted in the project but the investment was not subsidized.

Retooling production networks in a pharma sector that has for decades relied on cross-border exchange and international division of labour can only be done in incremental steps, cautioned Merck CEO Garijo.

“You cannot move a factory from one day to the other, this takes time,” she said.

(Reporting by Ludwig Burger and Patricia Weiss; Editing by Hugh Lawson)

Source Link Supply fears lead EU vaccine industry to seek home comforts

David Barret
David Barret

Related posts:

  1. U.S. Ex-Presidents Bush, Clinton, Obama band together to aid Afghan refugees
  2. Twitter re-opens its account verification process after another pause
  3. Apple’s new MagSafe wallet can be located with the ‘Find My’ app if it goes missing
  4. Report: NBA won’t mandate vaccine for players

Filed Under: News

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • Have You Seen This Snake? Florida Wants Your Help Finding Rare Species Seen Once In 50 Years
  • Plague Confirmed In Lake Tahoe Area For First Time In 5 Years, California Officials Say
  • Supergiant Star Spotted Blowing Milky Way’s Largest Bubble Of Its Kind, Surprising Astronomers
  • Game Theory Promised To Explain Human Decisions. Did It?
  • Genes, Hormones, And Hairstyling – Here Are Some Causes Of Hair Loss You Might Not Have Heard Of
  • Answer To 30-Year-Old Mystery Code Embedded In The Kryptos CIA Sculpture To Be Sold At Auction
  • Merry Mice: Human Brain Cells Transplanted Into Mice Reduce Anxiety And Depression
  • Asteroid-Bound NASA Mission Snaps Earth-Moon Portrait From 290 Million Kilometers Away
  • Forget State Mammals – Some States Have Official Dinosaurs, And They’re Awesome
  • Female Jumping Spiders Of Two Species Prefer The Sexy Red Males Of One, Leading To Hybridization
  • Why Is It So Difficult To Find New Moons In The Solar System?
  • New “Oxygen-Breathing” Crystal Could Recharge Fuel Cells And More
  • Some Gut Bacteria Cause Insomnia While Others Protect Against It, 400,000-Person Study Argues
  • Neanderthals And Homo Sapiens Got It On 100,000 Years Earlier Than We Thought
  • “Womb Of The Universe”: Native American Tribal Elders Help Archaeologists Decipher Ancient Rock Art In Missouri Cave
  • 16,000-Year-Old Paintings Suggest Prehistoric Humans Risked Their Lives To Enter “Shaman Training Cave”
  • Final Gasps Of A Dying Star Seen Through A Record-Breaking 130 Years Of Data
  • COVID-19 “Vaccine Alternative” Injection Could Be On Fast-Track To Approval From FDA
  • New Jersey Officials Investigate Possible First Locally Acquired Malaria Case Since 1991
  • First-of-Its-Kind Bright Orange Nurse Shark Recorded Off Costa Rica Makes History
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version